CureApp: World’s First Medical System Regulatory Approval of a Digital Remedy App for Hypertension

TOKYO–(COMMERCIAL WIRE)–CureApp, Inc. (Head Workplace: Chuo-ku, Tokyo; CEO: Kohta Satake) was notified by the Ministry of Well being, Labor and Welfare on April 26, 2022 that the corporate had acquired regulatory approval for medical units of a digital therapeutic app for Hypertension. That is the primary time that an impartial software program utility supporting physicians and sufferers has acquired medical system regulatory approval in Japan, and it’s the first utility addressing hypertension to be accredited on this planet. Preparations are actually underway to obtain the refund and launch the app in 2022.


Life-style modification is a critically vital a part of treating important hypertension, no matter blood stress classification. Nevertheless, life-style modifications depend upon the affected person’s mindset and motivation, and the work and residential setting, and are tough to take care of. Even with the involvement of a medical establishment, profitable implementation of such modifications requires an excessive amount of effort, and there are various limitations on what busy physicians can accomplish.

Numerous sufferers undergo from hypertension in Japan, about 70% of those sufferers haven’t reached their antihypertensive targets or haven’t acquired remedy. As well as, important hypertension presents the only largest danger issue for cerebrovascular illness and coronary heart illness*oneand medical bills associated to hypertension proceed to rise yr after yr*two.

*one: Supply: Pointers for the Administration of Hypertension 2019

*two: Ordinance of the fiscal yr 2019 of the Ministry of Well being, Labor and Welfare Normal abstract of nationwide medical expenditure

About this app

This app gives direct remedy steering that has been custom-made for every particular person affected person, together with recommendation on weight-reduction plan, train, sleep, and different facets of their life-style, and knowledge meant to encourage behavioral enhancements primarily based on the data entered by the consumer. affected person, by way of his smartphone. Encouraging life-style modifications and serving to sufferers purchase right life-style habits helps sufferers make sustainable life-style modifications, and goals to realize therapeutic efficacy within the type of blood stress discount by way of lowering salt consumption and weight reduction. The model of the app accessible to clinicians permits them to verify a affected person’s every day progress to implement life-style modifications and goals to make a major contribution to bettering the standard of healthcare supplied inside a restricted time frame. .

The fiscal yr 2022 revision of the nationwide medical cost system added the “Addition of medical administration of software program resembling medical system, and so on.”, and this marks the primary case of a stand-alone software program utility appearing as a health care provider and serving to the affected person which receives pharmaceutical approval. That is additionally the primary time on this planet that medical system regulatory approval has been granted for DTx*3 within the subject of hypertension.

*3: Abbreviation for Digital Therapeutics. Software program-based therapies.


Official identify

Adjunctive remedy utility for hypertension CureApp HT

generic identify

Hypertension adjuvant remedy program

Approval Quantity


Supposed use or impact

Adjuvant therapies of important hypertension in adults

Approval date

April 26, 2022

manufacturing and gross sales

Remedy App, Inc.

Abstract of scientific trials for this product

Efficacy of a digital remedy system in treating important hypertension: the pivotal HERB-DH1 trial

Kario et al. European Coronary heart Journal, Quantity 42, Quantity 40, October 21, 2021, Pages 4111–4122,

Firm Scientific Trial Outcomes Report (CureApp)

Message from Kohta Satake, MD and Consultant Director and CEO of CureApp, Inc.

We’re proud to announce a brand new digital remedy resolution for hypertension, as a follow-up to our digital remedy utility for nicotine habit. Hypertension is a illness that many undergo from in silence. It’s a notoriously tough illness to manage and deal with, requiring basic life-style modifications. Sufferers are likely to have a low sense of urgency to deal with this illness whereas they nonetheless have few subjective signs of the illness, and it’s tough to take care of the extent of conduct change wanted to handle the underlying causes of the illness. The app acts as a complementary remedy by offering steering throughout physician visits and helps sufferers exterior of visits to method life-style modifications in the appropriate approach to get to the foundation trigger. The app additionally gives physicians with a approach to compensate for measures applied throughout breaks in affected person remedy and their life-style habits, and permits them to ship higher high quality medical care that’s higher tailor-made to the wants of sufferers. every affected person.

Digital remedy will change into a regular type of remedy in Japan for each docs and sufferers, and we’ll proceed to hunt to develop DTx purposes that deal with different ailments.

About CureApp, Inc.

CureApp, Inc. is a MedTech firm that conducts analysis and growth for the creation of medical system applications, which apply superior software program expertise and medical proof to deal with illness, with the intent of producing and distributing them. The corporate is working onerous on creating “therapeutic apps” (apps used to deal with sicknesses) to change into the primary in Japan to determine a brand new healthcare service centered on “producing a therapeutic impact to deal with sicknesses utilizing an app.” In August 2020, CureApp was the primary to obtain medical system regulatory approval for a illness remedy app in Japan within the type of a nicotine habit remedy app, which was later reimbursed by the nationwide medical health insurance in December of the identical yr.

Companies through which CureApp participates

nicotine habit

Obtained medical system regulatory approval in August 2020; reimbursed by the Nationwide Well being Insurance coverage and prescriptions begin in December of the identical yr


Medical system regulatory approval acquired in April 2022


(Non-Alcoholic Steatohepatitis)

App at the moment underneath growth and in scientific trials with Tokyo College Hospital

Alcohol habit

Software at the moment underneath growth with the Kurihama Habit and Medical Middle of the Nationwide Hospital Group

Scientific trials underway at Okayama Metropolis Normal Medical Middle, Okayama Metropolis Hospital


Remedy utility for breast most cancers sufferers at the moment underneath growth with DAIICHI SANKYO COMPANY, LIMITED.

Power coronary heart failure

Software underneath growth with our companions at YUMINO Medical Company

Along with the above, we offer cell well being applications for personal firms by way of our “Ascure Give up Smoking Program” and “Particular Well being Information Ascure Give up Smoking Program”, which takes benefit of the information obtained within the growth of those therapeutics digital for medical establishments. These applications have been applied in additional than 230 firms and medical health insurance firms. Wanting forward, we’ll search to sequentially roll out this “Japan-developed digital well being resolution” world wide primarily based on the mannequin established in Japan.

CureApp, Inc. Firm Profile

Consultant Director and President

Kohta Satake

Head Workplace Tackle

Kodenma-Cho YS Constructing 4th Flooring 12-5, Nihonbashi Kodenma-Cho, Chuo-ku, Tokyo, Japan, 103-0001

US Department

CureApp North America, Inc.

Enterprise actions

Software program Improvement as a Medical System (SaMD), cell companies associated to well being


Spread the love

What do you think?

Leave a Reply